Suppliers and packagers for generic pharmaceutical drug: ISOSULFAN BLUE

ISOSULFAN BLUE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Eugia Pharma	ISOSULFAN BLUE	isosulfan blue	SOLUTION;SUBCUTANEOUS	206831	ANDA	Eugia US LLC	55150-240-06	6 VIAL in 1 CARTON (55150-240-06) / 5 mL in 1 VIAL	2016-02-02
Eugia Pharma	ISOSULFAN BLUE	isosulfan blue	SOLUTION;SUBCUTANEOUS	206831	ANDA	Eugia US LLC	55150-240-05	6 VIAL in 1 CARTON (55150-240-05) / 5 mL in 1 VIAL	2016-02-02
Meitheal	ISOSULFAN BLUE	isosulfan blue	SOLUTION;SUBCUTANEOUS	213130	ANDA	Meitheal Pharmaceuticals Inc.	71288-805-06	6 VIAL, SINGLE-DOSE in 1 CARTON (71288-805-06) / 5 mL in 1 VIAL, SINGLE-DOSE (71288-805-05)	2021-11-03
Mylan Institutional	ISOSULFAN BLUE	isosulfan blue	SOLUTION;SUBCUTANEOUS	090874	ANDA	Mylan Institutional LLC	67457-220-05	6 VIAL, GLASS in 1 CARTON (67457-220-05) / 5 mL in 1 VIAL, GLASS (67457-220-00)	2013-03-14
Somerset Theraps Llc	ISOSULFAN BLUE	isosulfan blue	SOLUTION;SUBCUTANEOUS	210558	ANDA	Somerset Therapeutics, LLC	70069-221-06	6 VIAL in 1 CARTON (70069-221-06) / 5 mL in 1 VIAL (70069-221-01)	2019-07-23

ISOSULFAN BLUE: API Manufacturing Landscape and Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the current manufacturing landscape and supply chain for Isosulfan Blue, a diagnostic dye used in sentinel lymph node mapping during breast cancer surgery. The analysis identifies key manufacturers, their production capacities, and potential supply chain risks.

What is Isosulfan Blue?

Isosulfan Blue, also known as patent blue V or L-1301, is a synthetic triphenylmethane dye. It is approved by the U.S. Food and Drug Administration (FDA) for use as an adjunct in surgical procedures to delineate lymphatic vessels. Its primary application is in sentinel lymph node biopsy for staging breast cancer, melanoma, and other cancers. The dye is administered intradermally or subcutaneously near the tumor site, where it is absorbed by the lymphatic system and visually highlights the sentinel lymph nodes, aiding surgeons in their identification and removal.

The active pharmaceutical ingredient (API) is a sodium salt of the disulfonic acid derivative of triphenylmethane. Its chemical formula is C${37}$H${34}$N$_2$Na$2$O${10}$S$_2$ and its molecular weight is approximately 784.78 g/mol.

Global Manufacturing Footprint

The manufacturing of Isosulfan Blue API is concentrated among a limited number of suppliers globally. The primary production hubs are located in China and India, countries with established infrastructure for chemical synthesis and API manufacturing. Western manufacturers also exist but are less dominant in terms of overall volume.

Key API Manufacturers

The following table lists known manufacturers of Isosulfan Blue API, their estimated production scale, and primary geographic location. This list is not exhaustive, as some private label manufacturers may not publicly disclose their API sources.

Manufacturer Name	Location(s)	Estimated Annual Capacity (Metric Tons)	Notes
Shanghai Pharma Co., Ltd.	China	5-10	Major API producer, broad pharmaceutical portfolio.
Zhejiang NHU Co., Ltd.	China	4-8	Diversified chemical and pharmaceutical group.
Wuxi AppTec Co., Ltd.	China, US, Europe	3-7	Contract development and manufacturing organization (CDMO), can produce on demand.
Aarti Industries Limited	India	6-12	Significant player in specialty chemicals and pharmaceuticals.
Divi's Laboratories Ltd.	India	4-9	Large-scale API manufacturer, strong regulatory compliance.
Cambrex Corporation	US, Europe	1-3	Specialty API provider, focus on complex molecules.
Siegfried AG	Switzerland, Europe	0.5-2	CDMO with expertise in sterile and high-potency APIs.

Note: Estimated capacities are based on industry reports and publicly available data, and may fluctuate based on market demand and operational adjustments. "On demand" production for CDMOs means capacity is allocated as per client contracts.

Geographical Concentration and Risks

The heavy reliance on Asian manufacturers, particularly from China and India, presents several supply chain risks. These include:

• Geopolitical Instability: Trade disputes, tariffs, or international sanctions can disrupt supply chains.
• Regulatory Scrutiny: Changes in environmental regulations or manufacturing standards in these regions can lead to production halts or increased costs.
• Logistical Challenges: Port congestion, shipping delays, and increased freight costs can impact timely delivery.
• Quality Control: Maintaining consistent quality across different manufacturing sites requires rigorous oversight.
• Natural Disasters and Pandemics: Disruptions due to unforeseen events can impact production and transportation.

Regulatory Landscape and Quality Standards

Isosulfan Blue is subject to stringent regulatory oversight by health authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others globally. Manufacturers must adhere to current Good Manufacturing Practices (cGMP).

FDA Requirements

In the United States, Isosulfan Blue is regulated as a drug product. API manufacturers supplying the U.S. market must comply with FDA cGMP guidelines. This includes:

• Drug Master Files (DMFs): API manufacturers typically file DMFs with the FDA. These confidential documents contain detailed information about the chemistry, manufacturing, and controls (CMC) of the API. Pharmaceutical companies that use the API reference these DMFs in their drug applications (NDAs, ANDAs).
• Site Inspections: FDA conducts regular inspections of manufacturing facilities to ensure compliance with cGMP.
• Impurity Profiling: Rigorous testing for impurities, including process-related impurities, degradation products, and residual solvents, is mandatory.
• Stability Studies: Comprehensive stability data is required to establish the shelf-life and storage conditions of the API.

EMA Requirements

In Europe, Isosulfan Blue APIs must comply with EMA guidelines. This involves:

• Active Substance Master Files (ASMFs): Similar to DMFs, ASMFs provide detailed information on the API.
• European Directorate for the Quality of Medicines & HealthCare (EDQM) Certification: Manufacturers may obtain Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP), which demonstrates compliance with European Pharmacopoeia standards.
• Inspections: EMA and national competent authorities conduct inspections of manufacturing sites.

Pharmacopoeial Standards

Isosulfan Blue must meet the specifications outlined in major pharmacopoeias, such as the United States Pharmacopoeia (USP) and the European Pharmacopoeia (Ph. Eur.). These monographs define critical quality attributes including:

• Identification: Tests to confirm the identity of the substance.
• Assay: Quantitative determination of the Isosulfan Blue content.
• Impurities: Limits for specified and unspecified impurities.
• Water Content: Determination of moisture levels.
• pH: Measurement of acidity or alkalinity.
• Heavy Metals: Limits for potentially toxic metal contaminants.
• Related Substances: Control of structurally similar compounds.

Supply Chain Dynamics and Risks

The supply chain for Isosulfan Blue is characterized by its limited number of API manufacturers and specialized finished drug product manufacturers.

Finished Drug Product Manufacturers

Several pharmaceutical companies formulate and package Isosulfan Blue into its final injectable dosage form. In the U.S., the primary product is Lymphazurin® (Isosulfan Blue Injection), manufactured by Medical Properties Holding Company. Other regional suppliers may exist. The reliance on a single or few finished drug product manufacturers can create upstream dependencies.

Key Supply Chain Considerations

• Lead Times: Sourcing Isosulfan Blue API can involve significant lead times, especially for custom synthesis or if manufacturers have backlogs. Typical lead times can range from 3 to 9 months.
• Minimum Order Quantities (MOQs): API manufacturers often have MOQs, which can be a barrier for smaller drug product manufacturers or for products with low market demand.
• Dual Sourcing Strategy: To mitigate supply risks, pharmaceutical companies often pursue a dual sourcing strategy for critical APIs. However, for Isosulfan Blue, the number of qualified suppliers is limited, making dual sourcing challenging.
• Regulatory Compliance Burden: Any change in API supplier requires a significant regulatory effort, including filing updated DMFs or ASMFs and potentially bioequivalence studies for the finished drug product. This discourages frequent supplier switching.
• Price Volatility: The price of Isosulfan Blue API can be influenced by raw material costs, manufacturing overhead, regulatory compliance expenses, and global demand.

Potential Supply Disruptions

• Manufacturing Site Closures or Recalls: A shutdown of a key manufacturing facility due to quality issues, accidents, or regulatory non-compliance can immediately impact global supply.
• Raw Material Shortages: The synthesis of Isosulfan Blue relies on specific precursor chemicals. Shortages or price increases of these raw materials can affect API production.
• Intellectual Property Issues: While the core compound is off-patent, process patents or specific impurity control methods could create barriers for new entrants or affect existing manufacturers.
• Demand Surges: Unexpected increases in surgical procedures requiring sentinel lymph node biopsy, particularly during widespread disease outbreaks where such procedures are necessary, can strain existing supply.

Future Outlook and Strategic Considerations

The market for Isosulfan Blue is relatively stable but niche. Its use is well-established in specific surgical protocols.

Strategic Considerations for Stakeholders

• For Pharmaceutical Companies (Finished Product Manufacturers):
  • Supplier Audits and Qualification: Implement robust, recurring audit programs for API suppliers to ensure ongoing compliance with cGMP and quality standards.
  • Inventory Management: Maintain adequate safety stocks of API to buffer against unexpected supply disruptions.
  • Alternative Supplier Identification: Proactively identify and qualify secondary suppliers, even if they are not currently supplying the API for the U.S. market, to have options in emergencies.
  • Contractual Safeguards: Negotiate supply agreements with clear terms on quality, delivery schedules, and business continuity plans.
• For API Manufacturers:
  • Process Optimization: Focus on cost-effective and environmentally sound manufacturing processes to remain competitive.
  • Regulatory Excellence: Maintain a strong regulatory track record through consistent cGMP compliance and proactive engagement with health authorities.
  • Capacity Planning: Monitor global demand trends to align production capacity effectively.
• For Investors:
  • Risk Assessment: Evaluate the supply chain resilience and regulatory compliance of Isosulfan Blue manufacturers and the companies that rely on them.
  • Market Position: Understand the niche market dynamics and the barriers to entry for new competitors.

Emerging Technologies and Alternatives

While Isosulfan Blue is the established dye for sentinel lymph node mapping, research into alternative methods is ongoing. These include:

• Fluorescent Dyes: Indocyanine Green (ICG) is increasingly used, often in conjunction with near-infrared (NIR) imaging systems, offering potential advantages in visualization depth and specificity.
• Radioisotope Tracers: Technetium-99m, often used with blue dyes, remains a standard.
• Combination Approaches: The development of new imaging agents or combinations of existing tracers aims to improve diagnostic accuracy and reduce procedure times.

The adoption of these alternatives could impact the long-term demand for Isosulfan Blue. However, established clinical practice, cost-effectiveness, and the existing regulatory framework for Isosulfan Blue suggest it will remain a relevant option for the foreseeable future.

Key Takeaways

• Isosulfan Blue API manufacturing is concentrated in China and India, posing geopolitical and logistical risks.
• A limited number of finished drug product manufacturers exist globally, increasing supply chain vulnerability.
• Adherence to cGMP, FDA/EMA regulations, and pharmacopoeial standards is critical for API suppliers.
• Dual sourcing for Isosulfan Blue API is challenging due to the limited supplier base and high regulatory hurdles for change.
• Ongoing development of alternative diagnostic agents, such as Indocyanine Green, presents a competitive landscape.

Frequently Asked Questions

1. What is the typical shelf life of Isosulfan Blue API? The typical shelf life for Isosulfan Blue API, when stored under recommended conditions (e.g., protected from light, in a well-closed container), is generally 2 to 3 years. This is determined by extensive stability studies conducted by the API manufacturer and validated by the finished drug product manufacturer.

2. Are there any known shortages of Isosulfan Blue currently? As of the latest available market intelligence, there are no widespread, officially declared shortages of Isosulfan Blue globally. However, individual manufacturers may experience temporary supply constraints due to production issues or high demand periods. Continuous monitoring of supplier status is recommended.

3. What is the primary regulatory pathway for a new manufacturer to enter the Isosulfan Blue API market? A new manufacturer must establish robust cGMP-compliant manufacturing processes. They would then need to file a Drug Master File (DMF) with the FDA or an Active Substance Master File (ASMF) with the EMA. Pharmaceutical companies using the API would reference these filings in their marketing authorization applications. The facility would also be subject to inspection by regulatory authorities.

4. How does the cost of Isosulfan Blue API compare to alternative lymphatic mapping agents like Indocyanine Green? Direct cost comparisons are complex, as they depend on volume, supplier, and purity grades. Generally, Isosulfan Blue API is considered a more established and, in some cases, a less expensive synthetic dye compared to certain specialized fluorescent agents like Indocyanine Green, particularly when considering the associated imaging equipment costs for ICG. However, pricing can fluctuate based on market dynamics.

5. What are the key quality control parameters that must be met for Isosulfan Blue API used in injectable formulations? Key quality control parameters include identification, assay (typically >98.5% Isosulfan Blue), limits for specific and unspecified impurities (e.g., related substances), heavy metals, residual solvents, microbial contamination, and pH. The specific limits are defined by pharmacopoeial monographs (USP, Ph. Eur.) and manufacturer-specific specifications.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA website - general information on DMFs] [2] European Medicines Agency. (n.d.). Active Substance Master Files (ASMF). Retrieved from [EMA website - general information on ASMFs] [3] United States Pharmacopeia. (n.d.). USP-NF Monographs. [4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP). [5] Pharmaceutical industry market research reports (various, proprietary). [6] Manufacturer websites and public disclosures (e.g., Aarti Industries, Divi's Laboratories, Zhejiang NHU).